Immunoglobulin G1, anti-(CC chemokine receptor CCR4) (human-mouse monoclonal
KW-0761 heavy chain), disulfide with human-mouse monoclonal KW-0761 κ-chain,
Immunoglobulin G1, anti-(human C-C chemokine receptor type 4 (CCR4, K5-5,
CD194)); humanized mouse monoclonal KW-0761 γ1 heavy chain (222-219′)-disulfide
with humanized mouse monoclonal KW-0761 κ light chain, dimer (228-228”:231-231”)-
MOLECULAR FORMULA C6520H10072N1736O2020S42 (peptide)
MOLECULAR WEIGHT 146.44 kDa (peptide)
SPONSOR Kyowa Hakko Kirin Co., Ltd.
CODE DESIGNATION KW-0761, KM8761
CAS REGISTRY NUMBER 1159266-37-1
THERAPEUTIC CLAIM Antineoplastic
Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4(CCR4). It has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.
Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd.
T-cell neoplasms, such as adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma, are particularly aggressive and, despite novel combination chemotherapy regimens, still have extremely…
View original post 1,396 more words